SCHEMBL5722795

SCHEMBL5722795

COC(=O)c1ccc(OC)c2oc(-c3ccccn3)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP1B1 Q16678 2/20 0.55
ADRA2A P08913 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
PDE4A P27815 7/20 0.47
PDE4B Q07343 5/20 0.47
PDE4C Q08493 5/20 0.47
PDE4D Q08499 5/20 0.47
AXL P30530 1/20 0.45
KDM4E B2RXH2 3/20 0.44
DHODH Q02127 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA3 P34903 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5722796 0.88 CYP1A1 (0.55) CYP1A1CYP1A2CYP1B1ADRA2AADRA2B
SCHEMBL5722709 0.84 PDE4A (0.66) CYP1A1CYP1A2CYP1B1PDE4APDE4B
SCHEMBL5723020 0.82 ADRA2A (0.49) CYP1A1CYP1A2CYP1B1ADRA2AADRA2B
SCHEMBL5723686 0.82 ALDH1A1 (0.53) CYP1A1CYP1A2CYP1B1ADRA2AADRA2B
SCHEMBL5722837 0.80 PDE4B (0.54) CYP1A1CYP1A2CYP1B1PDE4APDE4B
SCHEMBL5723067 0.79 PDE4D (0.52) CYP1A1CYP1A2CYP1B1PDE4APDE4B
SCHEMBL5722959 0.79 CYP1A1 (0.57) CYP1A1CYP1A2CYP1B1ADRA2AADRA2B
SCHEMBL5723007 0.77 KDM4E (0.45) CYP1A1CYP1A2CYP1B1PDE4APDE4B
SCHEMBL5723091 0.77 MAPT (0.45) CYP1A1CYP1A2CYP1B1ADRA2AADRA2B
SCHEMBL6837653 0.75 SMN1; SMN2 (0.60) CYP1A2PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0771794-B1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2006-05-03 EP disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
EP-0771794-A1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 CYP1A1 9/4885CYP1A2 103/4885CYP1B1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.